Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions.
Neurocrine Biosciences stock last closed at $152.72, up 1.26% from the previous day, and has increased 16.3% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 1.11 percentage points. Neurocrine Biosciences stock is currently +25.04% from its 52-week low of $122.14, and -17.95% from its 52-week high of $186.12.
There are currently 101.65M NBIX shares outstanding. The market cap of NBIX is $15.52B. In the last 24 hours, 1.25M NBIX shares were traded.
You need an online brokerage account to access the NASDAQ market and buy NBIX shares.
Based on our research, eToro is the best place to buy stocks. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, the next step is to fill out some personal info so you are able to buy NBIX today.
Now that you've finished signing up on a good stock buying app, you need to deposit funds:
Watch the tutorial below to see the process of transferring money into your new investment account.
Once you have identified the best place to buy Neurocrine Biosciences stock, it's very important to evaluate their stock before you invest, so you actually understand the risk as well as the upside.
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on NBIX's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge NBIX's intrinsic value.
Using relative valuations measures:
You can access more valuation analysis on NBIX's stock here.
Out of 21 Equities analysts who research NBIX, the consensus analyst rating on Neurocrine Biosciences is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Brian Abrahams, a top 10% analyst from RBC Capital maintains NBIX with a buy rating and raises their NBIX price target from $195.00 to $198.00, on Jul 31, 2026.
Phil Nadeau, a top 16% analyst from TD Cowen maintains NBIX with a strong buy rating and raises their NBIX price target from $200.00 to $220.00, on Jul 31, 2026.
David Amsellem, a top 4% analyst from Piper Sandler maintains NBIX with a strong buy rating and raises their NBIX price target from $207.00 to $210.00, on Jul 31, 2026.
Joshua Schimmer, a top 2% analyst from Cantor Fitzgerald maintains NBIX with a strong buy rating and raises their NBIX price target from $210.00 to $215.00, on Jul 31, 2026.
Yatin Suneja, a top 2% analyst from Guggenheim maintains NBIX with a strong buy rating and raises their NBIX price target from $200.00 to $222.00, on Jul 31, 2026.
Guggenheim's Yatin Suneja raised their price target on Neurocrine Biosciences (NASDAQ: NBIX) by 11% from $200 to $222 on 2026/07/31. The analyst maintained their Strong Buy rating on the stock.
Neurocrine Biosciences reported its Q2 2026 earnings.
Raising their price target, Suneja big-pictured that the company is well-positioned for sustained growth across its Ingrezza, Crenessity, and VYKAT XR franchises.
For Q2 2026, Neurocrine Biosciences reported:
For FY 2026, management guided:
CEO Kyle W. Gano, Ph.D., commented: "Our second quarter performance demonstrates the power of a strategy designed to compound over time.
"As our commercial portfolio of first-in-class medicines continues to grow, so does our capacity to reinvest in innovation, advance a differentiated late-stage pipeline and pursue strategic opportunities that strengthen the company for the long term.
"With multiple important clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we are building an enduring company poised to deliver meaningful value for patients and shareholders for years to come."
You can dive deeper into what analysts are forecasting on the Neurocrine Biosciences stock forecast page.
Last year, NBIX earnings were $705.50M. Over the past 5 year, NBIX's earnings have gone up by 12.51% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 7.23%.
Last year, NBIX revenue was $3.37B. Over the last five year, NBIX's revenue has grown by 26.74% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 9.16%.
Dig into NBIX's earnings and revenue performance here.
In the past year, insiders at NBIX have sold more shares than they have bought.
Leslie V. Norwalk, Director of NBIX, was the latest NBIX insider to buy. They bought $117,400.06 worth of NBIX shares on Jul 29, 2026.
Dig into more about who owns NBIX stock here.
No, Neurocrine Biosciences doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
There are two primary order types:
Press the Open button and your broker will place the order.
If you require additional help with buying stocks on eToro, click the how to video below:
Now that you own some shares in NBIX, you'll want to keep up with your company.
Add NBIX to a watchlist to track the latest developments regarding your NBIX stock.
To summarize, here are the 6 steps to buy Neurocrine Biosciences stock:
If you need a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest news on your new investment in Neurocrine Biosciences, get started below.